Rastislav Bahleda

6.1k total citations · 1 hit paper
65 papers, 1.9k citations indexed

About

Rastislav Bahleda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Rastislav Bahleda has authored 65 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 26 papers in Molecular Biology. Recurrent topics in Rastislav Bahleda's work include Fibroblast Growth Factor Research (14 papers), Lung Cancer Treatments and Mutations (14 papers) and Cancer Treatment and Pharmacology (13 papers). Rastislav Bahleda is often cited by papers focused on Fibroblast Growth Factor Research (14 papers), Lung Cancer Treatments and Mutations (14 papers) and Cancer Treatment and Pharmacology (13 papers). Rastislav Bahleda collaborates with scholars based in France, United States and Spain. Rastislav Bahleda's co-authors include Jean‐Charles Soria, Antoine Hollebecque, Antoîne Italiano, Anas Gazzah, Christophe Massard, Bob Zhong, Josep Tabernero, Jeffrey R. Infante, Hendrik‐Tobias Arkenau and Ben Tran and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Rastislav Bahleda

59 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

2021 171 citations Funda Meric‐Bernstam, Rastislav Bahleda et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rastislav Bahleda France	20	943	891	598	515	279	65	1.9k
Cinta Hierro Spain	19	700 0.7×	501 0.6×	368 0.6×	460 0.9×	167 0.6×	70	1.3k
Shuchi S. Pandya United States	19	980 1.0×	895 1.0×	900 1.5×	276 0.5×	365 1.3×	69	2.1k
Andreas H. Marx Germany	26	1.3k 1.4×	698 0.8×	822 1.4×	583 1.1×	301 1.1×	75	2.2k
Gina M. Vaccaro United States	20	1.2k 1.3×	494 0.6×	833 1.4×	1.1k 2.2×	373 1.3×	52	2.3k
N. Schleucher Germany	19	802 0.9×	598 0.7×	610 1.0×	359 0.7×	186 0.7×	32	1.6k
Jacqueline Vuky United States	25	1.4k 1.5×	565 0.6×	681 1.1×	1.4k 2.8×	279 1.0×	64	2.6k
Aparna Kalyan United States	26	1.1k 1.2×	802 0.9×	486 0.8×	550 1.1×	523 1.9×	66	2.1k
Marine Gross‐Goupil France	29	1.4k 1.5×	995 1.1×	1.9k 3.1×	532 1.0×	664 2.4×	175	2.9k
C. Logothetis United States	23	817 0.9×	690 0.8×	1.1k 1.8×	1.0k 1.9×	403 1.4×	71	2.4k
Julia Wilkerson United States	20	608 0.6×	501 0.6×	713 1.2×	188 0.4×	284 1.0×	44	1.8k

Countries citing papers authored by Rastislav Bahleda

Since Specialization

Citations

This map shows the geographic impact of Rastislav Bahleda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rastislav Bahleda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rastislav Bahleda more than expected).

Fields of papers citing papers by Rastislav Bahleda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rastislav Bahleda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rastislav Bahleda. The network helps show where Rastislav Bahleda may publish in the future.

Co-authorship network of co-authors of Rastislav Bahleda

This figure shows the co-authorship network connecting the top 25 collaborators of Rastislav Bahleda. A scholar is included among the top collaborators of Rastislav Bahleda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rastislav Bahleda. Rastislav Bahleda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Facchinetti, Francesco, Yohann Loriot, Floriane Brayé, et al.. (2024). Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2 -Driven Malignancies. Clinical Cancer Research. 30(21). 4943–4956. 17 indexed citations

Dufresne, Armelle, Mehdi Brahmi, Claire Cropet, et al.. (2024). 59MO COTESARC – A multicentre, phase I-II clinical trial evaluating the combination of MEK and PDL-1 inhibitors in patients (pts) with advanced soft tissue sarcoma (STS): Results from complex (CG) and simple genomic (SG) STS cohorts. ESMO Open. 9. 102449–102449.

Cesne, Axel Le, Claire Cropet, Mehdi Brahmi, et al.. (2024). LBA79 LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib. Annals of Oncology. 35. S1265–S1266. 1 indexed citations

Schöffski, Patrick, Rastislav Bahleda, Andrew J. Wagner, et al.. (2023). Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma. Clinical Cancer Research. 29(17). 3320–3328. 9 indexed citations

Nassif, Elise F., Jean‐Yves Blay, Christophe Massard, et al.. (2022). Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials. ESMO Open. 7(2). 100425–100425. 4 indexed citations

Meric‐Bernstam, Funda, Rastislav Bahleda, Cinta Hierro, et al.. (2021). Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study. Cancer Discovery. 12(2). 402–415. 171 indexed citations breakdown →

Nassif, Elise F., et al.. (2021). Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Frontiers in Immunology. 12. 775761–775761. 55 indexed citations

Tourneau, Christophe Le, Yungan Tao, Carlos Gomez‐Roca, et al.. (2020). Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research. 26(24). 6429–6436. 22 indexed citations

Even, Caroline, Matthieu Texier, Christophe Le Tourneau, et al.. (2020). 970P MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with docetaxel, cisplatin and 5-FU (DCF) as induction therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN). Annals of Oncology. 31. S682–S683. 2 indexed citations

10.

Sun, Roger, Stéphane Champiat, Jean‐Marie Michot, et al.. (2020). 1050P Does immunotherapy impact the outcomes of future anti-tumour therapies?. Annals of Oncology. 31. S718–S719. 1 indexed citations

11.

Bahleda, Rastislav, Antoîne Italiano, Cinta Hierro, et al.. (2019). Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clinical Cancer Research. 25(16). 4888–4897. 187 indexed citations

12.

Facchinetti, Francesco, Antoine Hollebecque, Rastislav Bahleda, et al.. (2019). Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors. Clinical Cancer Research. 26(4). 764–774. 88 indexed citations

13.

Bahleda, Rastislav, Funda Meric‐Bernstam, Lipika Goyal, et al.. (2018). Phase I dose-escalation study of TAS-120, a highly selective, covalently bound FGFR inhibitor, in patients with advanced solid tumors. Clinical Trials. 78(13). 1 indexed citations

14.

Mahjoubi, Linda, Franco Cecchi, Christophe Massard, et al.. (2018). Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. Tumori Journal. 104(6). NP38–NP41.

15.

Tran, Ben, Funda Meric‐Bernstam, Hendrik‐Tobias Arkenau, et al.. (2018). Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi’s. Annals of Oncology. 29. ix49–ix50. 15 indexed citations

16.

Karkera, Jayaprakash D., Dana Gaffney, Ademi Santiago-Walker, et al.. (2017). Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib. Molecular Cancer Therapeutics. 16(8). 1717–1726. 43 indexed citations

17.

Bahleda, Rastislav, Fadi S. Braiteh, Ani Sarkis Balmanoukian, et al.. (2017). Long-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase Ia Trial Results. Annals of Oncology. 28. v373–v373. 21 indexed citations

18.

Bigot, Frédéric, Antoine Hollebecque, Alberto Carmona‐Bayonas, et al.. (2016). Identification of new prognostic factors in phase I patients treated by immunotherapy. Annals of Oncology. 27. vi124–vi124. 2 indexed citations

19.

Bahleda, Rastislav, Antoine Hollebecque, Andréa Varga, et al.. (2015). Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. British Journal of Cancer. 113(10). 1413–1420. 16 indexed citations

20.

Sessa, Cristiana, Patricia LoRusso, Anthony W. Tolcher, et al.. (2013). Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(17). 4832–4842. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact